Inactive Instrument

News Ocata Therapeutics Inc

Equities

US67457L1008

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ocata Therapeutics : Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries	16-02-10	PR
Ocata Therapeutics : Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics	16-01-22	PR
Ocata Therapeutics : Reports the Publication of Data about the Generation of Corneal Endothelial Cells from Human Pluripotent Stem Cells	15-12-28	BU
Ocata Therapeutics : Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis	15-12-03	BU
OCATA THERAPEUTICS : Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Astellas Pharma Inc.	15-11-11	BU
Ocata Therapeutics : Brower Piven Commences An Investigation Into The Proposed Sale Of Ocata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information	15-11-10	BU
Ocata Therapeutics : Astellas to Acquire Ocata Therapeutics	15-11-09	PR
Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Third Quarter of 2015	15-11-06	BU
Ocata Therapeutics : to Present at Ladenburg Thalmann 2015 Healthcare Conference	15-09-23	BU
Ocata Therapeutics : Canine Patients Treated with Ocata’s Hemangio-derived Mesenchymal Cells (HMC™) Achieve Remission in a Model of Crohn’s Disease	15-09-22	BU
Ocata Therapeutics : First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD	15-09-08	BU
Ocata Therapeutics : Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics Awarded the Honor of iPSC Industry Influencer	15-09-03	BU
Ocata Therapeutics : Receives SBIR Grant from the NIH’s National Eye Institute to Develop Proprietary Photoreceptor Progenitor Cell Therapy for Retinitis Pigmentosa	15-09-01	BU
Ocata Therapeutics : Appoints Dr. Brian Levy to its Board of Directors	15-08-31	BU
Ocata Therapeutics : Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis	15-08-24	BU
Ocata Therapeutics : Secures $10 Million in Debt Financing	15-08-19	BU
Ocata Therapeutics : Provides Corporate Update for the Second Quarter of 2015	15-08-06	BU
Ocata Therapeutics : to Host Conference Call and Webcast to Provide Corporate Update for the Second Quarter of 2015	15-07-31	BU
Ocata Therapeutics : Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases	15-07-15	BU
Ocata Therapeutics : Announces New Pre-Clinical Data to be Reported at the International Congress on Systemic Lupus Erythematosus	15-07-14	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Ocata Therapeutics Inc

Equities

US67457L1008

Summary

Filters